Valion Bio
VBIO
9 hedge funds and large institutions have $90.7K invested in Valion Bio in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
30% more capital invested
Capital invested by funds: $69.8K → $90.7K (+$20.9K)
0.1% less ownership
Funds ownership: 0.27% → 0.17% (-0.1%)
10% less funds holding
Funds holding: 10 → 9 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$16.1K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$10.6K |
| 3 |
Two Sigma Investments
New York
|
+$3.33K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$144 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$10.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$7.12K |
| 3 |
VF
Virtu Financial
New York
|
-$5K |
| 4 |
Renaissance Technologies
New York
|
-$4.39K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
1
HRT Financial
New York
| $19K | +$16.1K | +3,450 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $19K | -$10.8K | -2,323 | -42% |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $16.3K | – | – | – |
|
|
GSC
4
Ground Swell Capital
Folly Beach,
South Carolina
| $13.1K | +$10.6K | +2,269 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $12.4K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $6.53K | +$144 | +31 | +3% |
|
|
7
Two Sigma Investments
New York
| $4.21K | +$3.33K | +715 | New |
|
|
SS
8
SBI Securities
Tokyo,
Japan
| $106 | +$84 | +18 | New |
|
|
9
Bank of America
Charlotte,
North Carolina
| $24 | +$5 | +1 | +33% |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$7.12K | -1,678 | Closed |
|
|
VF
11
Virtu Financial
New York
| – | -$5K | -1,232 | Closed |
|
|
12
Renaissance Technologies
New York
| – | -$4.39K | -1,035 | Closed |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$3.93K | -927 | Closed |
|
14
Osaic Holdings
Scottsdale,
Arizona
| – | -$35 | -8 | Closed |
|
VBIO Hedge Fund Activity: Q4 2024 in Review
9 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2024, worth a combined $90.7K — up 30% from $69.8K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VBIO and 4 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $16.1K. The largest seller was UBS Group, cutting an estimated $10.8K.
- 9 institutional investors held Valion Bio (VBIO) as of Q4 2024, down from 10 in Q3 2024.
- Funds reported $90.7K of Valion Bio stock for Q4 2024, up 30% quarter-over-quarter.
- 4 funds opened new Valion Bio positions in Q4 2024 and 5 closed out, a net change of -1 holder.
- The largest Valion Bio buyer in Q4 2024 was HRT Financial, an estimated $16.1K added.
- The largest Valion Bio seller in Q4 2024 was UBS Group, an estimated $10.8K sold.
Based on aggregated 13F filings for Q4 2024.